A total of 195 case of pancreatic cancer have been diagnosed in the Kingdom of Saudi Arabia (KSA) in 2010 accounting for 2.5% of all cancers for that year.[@ref1] The age standardized rate was 2.2/100,000 for males and 1.6/100,000 for females.

A committee of experts in the medical and surgical treatment of pancreatic cancer was established under the supervision of the Saudi Oncology Society (SOS).

The evidence adopted in these guidelines is rated at 3 levels: 1) Evidence level (EL)-1 (highest level) evidence from phase III randomized trials or meta-analyses; 2) EL-2 (intermediate-level) evidence from good phase II trials or phase III trials with limitations; and 3) EL-3 (low-level) from retrospective or observational data and/or expert opinion. This easy-to-follow grading system is convenient for the reader and allows accurate assessment of the applicability of the guidelines in individual patients.[@ref2]

All pancreatic cancer cases are preferably seen or discussed in a multidisciplinary form.

**Pre-treatment evaluation**1.1Clinical examination, including age, performance status (PS), and degree of weight loss1.2Blood count, liver, and renal function1.3Tumor marker: CA19.9 level1.4Computed tomography (CT) scan of chest, abdomen, and pelvis (preferably triple phase, spiral)[@ref5] (EL-1)1.5Endoscopic ultrasound (EUS) (optional) ± fine-needle aspiration (EL-2)1.6Endoscopic retrograde cholangio-pancreatography (ERCP) (EL-2)1.7Positron emission tomography (PET) scan (optional) (EL-2)1.8Laparoscopy in resectable cases (optional) (EL-2)**Surgical pathology report requirement.** The following parameters should be mentioned in all surgical pathology reports of pancreatic cancer:2.1Specimen type2.2Tumor size2.3Histologic grade: G2.4Primary tumor extent of invasion: T2.5Regional lymph node: N2.5.1Number of nodes recovered2.5.2Number of nodes involved2.6Metastasis: M2.7Margins: surgical clearance in mm2.8Whipple's resection2.8.1.Superior mesenteric artery (SMA) margin2.8.2.Post margin2.8.3.Portal vein margin2.8.4.Pancreatic neck margin2.8.5.Enteric margin2.9Lymphatic invasion: L2.10Vascular invasion: V2.11Perineural invasion: P2.12Final stage: G, T, N, M, L, V, P**Staging classifications:**The American Joint Commission on Cancer (AJCC)- 2007 pathological staging system will be used.[@ref3]**Treatment:**4.1Assessment of resectability: Tumors will be considered4.1.1Resectable: if there are clear fat planes around celiac trunk and superior mesenteric artery (SMA), and have patent superior mesenteric vein (SMV) and portal vein4.1.2Unresectable: if there is invasion of celiac trunk and SMA or if there is an occlusion of SMV or portal vein. Invasion of the superior mesenteric or portal vein is no longer an absolute contraindication. These veins can be resected partially with as much as 50% narrowing of the lumen4.1.3Borderline resectable: those are defined as one in which there is high likelihood of an incomplete resection (R1 or R2)[@ref4],[@ref5]4.2Management of resectable pancreatic cancer:4.2.1Laparotomy and pancreatico-duodenectomy.[@ref6],[@ref7] This should only be performed in a tertiary care facility. Pre-operative biopsy is not required4.2.2Adjuvant chemotherapy for 6 months. This is offered to all patients with pathological stage: T1-T4, N0-N1, and R0-R1 resection. Treatment consists of single agent gemcitabine at a dose of 1000 mg/m^2^ on days one, 8, and 15. Cycle repeated every 28 days, for a total of 6 cycles[@ref8] (EL-1)4.2.3Post-operative radiation is a possible option for R1-R2 resection. Radiotherapy dose should be 45-54 Gy (1.8-2.0 Gy/day) (EL-2)4.3Management of borderline resectable pancreatic cancer: options include one of the following:4.3.1Planned upfront resection. Further therapy will depend on findings during surgery:4.3.1.1If found resectable: perform pancreatico-doudenectomy followed by adjuvant chemotherapy (see Item 4.2.2) (EL-1)4.3.1.2If found unresectable: perform biopsy, consider doing bypass surgery and celiac plexus block. Postoperatively, patients can be offered chemotherapy alone (see item 4.4.2) or chemoradiotherapy[@ref11] (EL-2).4.3.1.2.1Options of chemotherapy with concurrent radiotherapy include:4.3.1.2.1.15-fluorouracil 500 mg/m^2^ daily for 3 days cycle repeated after 4 weeks[@ref12] (EL-2)4.3.1.2.1.2Capecitabine at a daily dose of 800 mg/m^2^ BID for 5 days per week for the duration of irradiation[@ref9] (EL-2)4.3.1.2.1.3Gemcitabine 300-600 mg/m^2^ weekly during irradiation.4.3.1.2.2Radiotherapy dose should be 45-54 Gy (1.8-2.0 Gy/day) [@ref10] (EL-2)4.3.2Planned for upfront neoadjuvant therapy. Patient should have confirmatory tissue biopsy followed by either palliative chemotherapy (EL-2) or chemoradiotherapy (EL-2) (see item 4.3.1.2.1 and 4.3.1.2.2). Patients with major response can be considered for re-exploration and possible resection.4.4Management of locally advanced, unresectable pancreatic cancer. Patients should have the following:4.4.1Tissue biopsy4.4.2Palliative chemotherapy with one of the following options:4.4.2.1Single agent gemcitabine: dose of 1000 mg/m^2^ on days one, 8, 15. Cycle repeated every 28 days, until progression (EL-1)4.4.2.2Gemcitabine based combinations (gemcitabine + fluoropyrimidines or gemcitabine + cisplatin)[@ref11] (EL-1)4.4.2.3FOLFORINOX combination chemotherapy[@ref12] (combination of 5-fluorouracil, leucovorin, oxaliplatin and irinotecan) in patients with PS 0-1 by ECOG scale (EL-1)4.4.3Palliative chemoradiotherapy using gemcitabine 11 (see item 4.3.1.2.1.3)4.5Management of metastatic pancreatic cancer. Patients may be offered palliative chemotherapy. The choice depends on patient age, PS, and patient choice after an informed consent. Chemotherapy is given until disease progression or unacceptable toxicity. Those options include:4.5.1Single agent gemcitabine (EL-1)4.5.2Gemcitabine based combinations (gemcitabine + fluoropyrimidines[@ref13] or gemcitabine + cisplatin[@ref11] or gemcitabine + nab-paclitaxel[@ref14]) (EL-1)4.5.3FOLFORINOX combination chemotherapy[@ref12] in patients with PS 0-1 by Eastern Cooperative Oncology Group (ECOG) scale (EL-1)4.5.4Patients not fit for chemotherapy should be given best supportive care. This includes, but is not restricted to pain management (including nerve block of celiac plexus, stenting for biliary obstruction. and duodenal obstruction)4.6Management of locally recurrent disease: options include4.6.1Concurrent gemcitabine and radiotherapy. Radiotherapy dose should be 45-54 Gy (1.8-2.0 Gy/day)[@ref9] (EL-1)4.6.2Palliative chemotherapy (see item 4.5) (EL-1)4.6.3Best supportive care for unfit patients (see item 4.5.4)
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